WuXi Biologics (2269) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of WuXi Biologics stock HK$53.55, price HK$48.68, upside +10.0%, quality 68 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range HK$10.26 – HK$145.60 · fair‑value band HK$36.20 – HK$91.79 · the HK$48.68 price screens below the HK$53.55 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow WuXi Biologics in your weekly email
Every Wednesday you see whether WuXi Biologics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil.
Show moreShow less
It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Tumor Associated Antigens ("TAA") mAb Technology, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.
It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; research and development in relation to biologics; international sales contracting service; vaccine contract development and manufacturing organization (CDMO) and related business; development, production, and distribution of biotechnological products; and engages in investment and material supplier activities.
WuXi Biologics (Cayman) Inc. was incorporated in 2014 and is headquartered in Wuxi, China.
Stock analysis
WuXi Biologics (2269) currently trades at HK$48.68, while our model-based Fair Value estimate is HK$53.55, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$65.11 per share, and 8 of the 24 models we run sit above the HK$48.68 price.
Bear case: the Economic Profit group reads lowest at HK$13.59, and 16 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: HK$36.20 (bear) to HK$91.79 (bull), the price of HK$48.68 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
WuXi Biologics reported revenue of 21.8B CNY in FY2025 versus 10.3B CNY in FY2021, a compound +20.6%/yr. Reported net income was 4.9B CNY in FY2025, compounding +9.7%/yr from FY2021.
Key figures
Market cap HK$204B (≈ $26.0B) Large · P/E ratio 37.4 · P/S ratio 8.42 · Net margin 22.5% · Return on equity 11.4% · Return on assets (EBIT) 9.0% · Operating margin 31.6% · Revenue (TTM) 23.6B CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 70 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 64% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at 10%, 2269 screens cheaper than that median.
Fair Value models
BearHK$36.20Fair Value HK$53.55BullHK$91.79
Price HK$48.68 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+16.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.2%
Start year 2020 (pandemic). Over 10 years: +44.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+23.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.2% vs 56.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 31%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+16.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +24.3% a year for the price and +14.6% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+10.0% · Top 25%
Profitability
Return on equity (12 months)11.4% · Top 25%
Return on assets7.7% · Top 25%
Net margin (12 months)21.2% · Top 25%
Operating margin (12 months)31.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)18.4% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "WuXi Biologics Fair Value". https://www.fairvalue-calculator.com/stock/2269
Frequently asked questions
Is WuXi Biologics (2269) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of HK$53.55 versus a price of HK$48.68, about +10% upside (fairly valued).
What is the fair value of 2269?
Our model-based fair value for WuXi Biologics is HK$53.55 (as of Nov 5, 2026), built from audited fundamentals. The current price: HK$48.68.
What is the quality score of 2269?
WuXi Biologics has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for WuXi Biologics (2269)?
Our model-based price target is the fair value of HK$53.55 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario HK$36.20, optimistic scenario HK$91.79. It is a calculation from audited fundamentals, not an analyst target.
What is the WuXi Biologics stock forecast for 2026?
Our models put fair value at HK$53.55, about +10% upside versus a price of HK$48.68 (fairly valued). Cautious scenario HK$36.20, optimistic scenario HK$91.79. The calculation is refreshed regularly with new filings.
What is the revenue of WuXi Biologics (2269)?
WuXi Biologics reported trailing-twelve-month revenue of about 23.6B CNY (latest available figure, as of Nov 5, 2026).
What growth is priced into WuXi Biologics (2269)?
For today's price to be fair in a discounted-cash-flow model, WuXi Biologics would have to grow free cash flow by +26.4 % per year for five years (discount rate 8.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +31.2 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 2269 use?
Our models discount WuXi Biologics at 8.8 %: a base by market capitalisation (large), damped by beta 0.59, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For WuXi Biologics that is +26.4 % per year a year over ten years, using the same discount rate (8.8 %) and the same formula as our fair value.
How much growth has WuXi Biologics (2269) delivered so far?
Over the past 5 years revenue at WuXi Biologics grew +31.2 % a year. The price currently implies +26.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of WuXi Biologics (2269) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into WuXi Biologics (+26.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of WuXi Biologics (2269)?
The free-cash-flow yield on the price is 1.62 %: that much free cash flow WuXi Biologics produces per unit of market value. When it exceeds the discount rate of our models (8.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of WuXi Biologics (2269)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For WuXi Biologics it is HK$53.55 per share (as of Nov 5, 2026), against a price of HK$48.68. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is WuXi Biologics stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 2269 trades below its calculated fair value: price HK$48.68, fair value HK$53.55, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2269?
No. The price is what the market pays today (HK$48.68); the fair value is what the company's own numbers justify (HK$53.55). For WuXi Biologics the two are HK$4.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is WuXi Biologics worth?
The market values WuXi Biologics at about HK$204B (market capitalisation, as of Nov 5, 2026). Per share that is HK$48.68; our models calculate a fair value of HK$53.55 per share.
What do the bullish and bearish scenarios say about 2269?
Our models span a range for WuXi Biologics: cautious scenario HK$36.20, base HK$53.55, optimistic HK$91.79 per share (as of Nov 5, 2026, price HK$48.68). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2269?
WuXi Biologics trades at a price-to-earnings ratio of 37.4 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$53.55 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2020 to 2025), reported earnings: 43.7. Other multiples: PEG 0.7, P/B 3.7, P/S 7.3, EV/EBITDA 18.2.
What is the PEG ratio of 2269?
The PEG ratio of WuXi Biologics is 0.71 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of WuXi Biologics (2269)?
Balance-sheet figures for WuXi Biologics (as of Nov 5, 2026): return on equity 11.4%, debt of 0.00 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 2269 from its 52-week high?
WuXi Biologics trades at HK$48.68, about 16% below its 52-week high of HK$57.90 and 64% above the low of HK$29.70 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of HK$53.55 is for.
Which stocks are comparable to WuXi Biologics?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is WuXi Biologics stock attractive at the current price?
The data as of Nov 5, 2026: price HK$48.68, calculated fair value HK$53.55 (+10%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2269 calculated?
We run WuXi Biologics through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$53.55, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. WuXi Biologics currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of WuXi Biologics (2269)?
The closing price on Nov 5, 2026 was HK$48.68. Our model-based fair value is HK$53.55, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with WuXi Biologics right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$36.20 to HK$91.79) leaves room in how you read the outcome.
Where does the earnings growth of WuXi Biologics (2269) come from?
Earnings per share at WuXi Biologics grew +51.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +42.7 %, EBIT margin +5.8 %, tax rate +0.1 %, residual (interest, one-offs) +0.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of WuXi Biologics
How large is the market capitalisation of WuXi Biologics (2269)?
The market capitalisation of WuXi Biologics is HK$204B (≈ $26.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of WuXi Biologics (2269)?
The price-to-sales ratio of WuXi Biologics is 8.42 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of WuXi Biologics (2269)?
The net margin of WuXi Biologics is 22.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of WuXi Biologics (2269)?
The return on equity (ROE) of WuXi Biologics is 11.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of WuXi Biologics (2269)?
On an EBIT basis the return on assets of WuXi Biologics is 9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of WuXi Biologics (2269)?
The operating margin of WuXi Biologics is 31.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at WuXi Biologics (2269)?
Revenue at WuXi Biologics is growing +18.4% versus a year earlier (3y avg +12.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at WuXi Biologics (2269)?
Earnings per share at WuXi Biologics are growing +4.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does WuXi Biologics (2269) hold?
WuXi Biologics holds more cash than debt, 6.1B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch WuXi Biologics in the live analysis
One click puts WuXi Biologics on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026